LONG-TERM EVENTS IN SIROLIMUS-ELUTING STENTS:LONG-TERM EVENTS IN SIROLIMUS-ELUTING STENTS:

a specific focus on diseased saphenous vein grafts a specific focus on diseased saphenous vein grafts from the randomized DELAYED-RRISC trialfrom the randomized DELAYED-RRISC trial

Pierfrancesco Agostoni, MDPierfrancesco Agostoni, MD

On behalf of the On behalf of the DELAYED-RRISC DELAYED-RRISC ((DDeath and eath and EEvents at vents at LLong-term ong-term follow up follow up AAnalnalYYsis: sis: EExtended xtended DDuration of the uration of the RReduction of eduction of

RRestenosis estenosis IIn n SSaphenous vein grafts with aphenous vein grafts with CCypher stentypher stent)) Investigators Investigators

Antwerp Cardiovascular Institute MiddelheimAntwerp Cardiovascular Institute MiddelheimAntwerp, BelgiumAntwerp, Belgium

RRISC TrialReduction of Restenosis In

Saphenous vein grafts with Cypher stent

• Prospective, randomized, double-blind, non industry sponsored, single center, trial comparing SES vs. BMS in SVG lesions

• 75 patients with 96 lesions localized in 80 diseased SVG were included

• Enrollment: September 2003-November 2004

• Primary endpoint : 6-month in-stent late loss

• Secondary endpoints (all at 6 months follow up): – Binary angiographic restenosis (in-stent/in-segment)– Clinical events (death, MI, TLR, TVR)

Vermeersch, Agostoni et al. JACC 2006

• Major Inclusion Criteria• De novo lesion (stenosis >50%) in a diseased SVG• Diameter ranging between 2.5 and 4.0 mm• Diagnosis of angina pectoris

Osial stenoses & thrombotic/calcific stenoses were allowedNo maximum lesion length prespecified

• Major Exclusion Criteria• Impaired renal function • Prior stent within 5 mm of target lesion• Totally occluded vein grafts• Documented LV Ejection Fraction <25%• Distal anastomotic stenosis • Prior brachytherapy in the index vessel• Recent MI (<7 days)

RRISC TrialReduction of Restenosis In

Saphenous vein grafts with Cypher stent

Vermeersch, Agostoni et al. JACC 2006

75 patients (with 96 lesions) meeting the inclusion criteria

37 patients (49 lesions) randomized to BMS

38 patients (47 lesions) randomized to SES

37 patients (49 lesions) available for 6-month angiographic follow up

35 patients (44 lesions) available for 6-month angiographic follow up

1 patient died2 patients refused angio follow up

randomization

No patient was lost to follow up. All patients, but 1 (dead) available for 6-month clinical follow up.

204 patients screened(September 2003-November 2004)

Patients excluded (reason):2 patients (age >85 years)18 patients (acute MI)7 patients (MI within the last 7 days)3 patients (creatinine >3 mg/dL)40 patients (vein graft with RVD >4.0 mm)12 patients (distal anastomotic disease)38 patients (restenotic lesions)8 patients (enrolled in other trials)1 patient (no informed consent)

Vermeersch, Agostoni et al. JACC 2006

BMS(n=37)

SES(n=38)

P-value

Age (years) 72 ± 8 73 ± 7 0.36Men 33 (89%) 31 (82%) 0.36Family history 29 (78%) 25 (66%) 0.23Hypertension 21 (57%) 22 (58%) 0.84Hypercholesterolemia 31 (84%) 33 (87%) 0.74Current smoker 4 (11%) 2 (5%) 0.46Diabetes Mellitus 5 (14%) 6 (16%) 0.78Body mass index (Kg/m2) 26.4 ± 3.9 26.4 ± 3.1 0.97History of heart failure 7 (19%) 6 (16%) 0.72Prior myocardial infarction 15 (41%) 17 (45%) 0.71Prior coronary angioplasty 15 (41%) 12 (32%) 0.42Unstable angina pectoris 19 (51%) 23 (60%) 0.41Ejection Fraction (%) 72 ± 12 68 ± 18 0.37Age of the grafts (years) 12.6 ± 5.9 12.4 ± 4.6 0.92

Baseline characteristics

Vermeersch, Agostoni et al. JACC 2006

BMS(lesions=49)

SES(lesions=47)

P-value

Degenerated saphenous vein grafts 17 (41.5%) 19 (48.7%) 0.51Recipient native vessel territory 0.11

Left anterior descending/diagonal 6 (12.2%) 9 (19.2%)

Circumflex/obtuse marginal 26 (53.1%) 15 (31.9%)

Right coronary artery 17 (34.7%) 23 (48.9%)

Angiographic evidence/suspect of thrombus 12 (24.5%) 17 (36.2%) 0.21Moderately/heavily calcified lesions 9 (18.4%) 8 (17%) 0.86Number of stents per patient 1.46 ± 0.7 1.58 ± 0.7 0.45Number of stents per lesion 1.11 ± 0.3 1.28 ± 0.5 0.14Total stent length per patient (mm) 33.4 ± 18.2 36.9 ± 17.6 0.39Total stent length per lesion (mm) 25.2 ± 11.9 29.9 ± 15.6 0.11Stent diameter (mm) 3.36 ± 0.26 3.41 ± 0.19 0.72Successful direct stenting 44 (89.8%) 44 (93.6%) 0.50Post-dilatation 7 (14.3%) 14 (29.8%) 0.09Maximal balloon diameter (mm) 3.44 ± 0.38 3.56 ± 0.37 0.09Maximal inflation pressure (atm) 18.8 ± 2.2 18.7 ± 2.8 0.85Vermeersch, Agostoni et al. JACC 2006

0.20

0.40

0.60

0.80

1.00

0.17 0.17 0.79 0.38 0.24 0.19

p=0.001

p=0.9 p=0.6

0.70 0.41

p=0.01

Prox edge Dist edgeIn-stent In-segment

Late Loss Analysis

Vermeersch, Agostoni et al. JACC 2006

BMSSES

In-segment

10

20

30

40

11.4%30.6% 13.6%32.7%

p=0.024 p=0.031

In-stent

Δ=19.1%RRR=0.58

Δ=19.2%RRR=0.63

BMSSES

Binary Restenosis

Vermeersch, Agostoni et al. JACC 2006

6-month MACE

BMSn=3737

SESn=3838 P value

In-hospitalDeath 0 0Repeat revascularization 0 0Periprocedural MI 1 (2.7%) 2 (5.3%) 0.99

Between discharge and 6 monthsDeath 0 1 (2.6%) 0.99Myocardial infarction 0 1 (2.6%) 0.99TLRTLR (per-patient) 8 (21.6%) 2 (5.3%) 0.0470.047TVRTVR (per-patient) 10 (27%) 2 (5.3%) 0.0120.012

Cumulative 6-month MACE 11 (29.7%) 6 (15.8%) 0.15

- Due to safety issues recently raised with DES(ESC/WCC 2006), we decided to further follow upour patients, in order to analyze long-term events.

-In September 2006, a new approval was obtainedfrom the local Ethics Committee to extend the follow-up.

-A new informed consent was obtained fromall the patients.

-All patients were contacted between Septemberand December 2006 (no lost to follow up).

-Blinding was maintained for patients andreferring physicians/cardiologists.

Vermeersch, Agostoni et al. JACC 2006

BMSn=3737

SESn=3838 P value

Death 0 10 (26.3%) 0.001

Myocardial infarction 1 (2.7%) 4 (10.5%) 0.35

TLR 3 (8.1%) 7 (18.4%) 0.30

TVR 4 (10.8%) 11 (28.9%) 0.05

MACE after 6-monthup to 32 months (median f.u.)

BMSn=3737

SESn=3838 P value

Death 0 11 (28.9%) <0.001Myocardial infarction 2 (5.4%) 7 (18.4%) 0.15TLR 11 (29.7%) 9 (23.7%) 0.55TVR 14 (37.8%) 13 (34.2%) 0.74MACE 15 (40.5%) 22 (57.9%) 0.13

Other PCI (not TLR/TVR) 14 (37.8%) 12 (31.6%) 0.57Double anti-platelet therapy 19 (51.4%) 19 (50%) 0.91Single anti-platelet therapy 14 (37.8%) 15 (39.5%) 0.88No anti-platelet therapy 4 (10.8%) 4 (10.5%) 0.97Statin therapy 27 (73%) 29 (76.5%) 0.74

Cumulative MACE

Stent Thrombosis(ARC criteria)

BMSn=3737

SESn=3838 P value

Definite 0 2 (5.2%)1 fatal at 13 months

1 non fatal at 30 months

0.49

Probable 0 0 -

Possible 0 3 (7.9%)1 sudden death at 7.5 months1 sudden death at 11.5 months1 sudden death at 35 months

0.30

Total 0 5 (13.1%) 0.054 Fisher Exact0.022 Log Rank

Time Cause of death Anti-thrombotic therapy

5 months progressive heart failure TP7.5 months sudden out-of-hospital death TP, W

11.5 months sudden out-of-hospital death ASA, TP14.5 months progressive heart failure after MI due to

thrombosis of the index stent-

(suspended 1 week before MI for knee surgery)16 months metastatic urothelial carcinoma -

(stop 1 month before for severe anemia)19 months metastatic colon carcinoma -

(stop 2 months before for anorexia)22 months progressive MOF after peri-operative (limb ischemia) MI

(no stent thrombosis of the stent)-

(suspended 1 week before MI for AICD change)23.5 months post-operative (AVR and ReDo CABG

for progression of CAD) infectionASA, TP

30 months progressive Parkinson disease ASA, TP33 months progressive MOF after ReDo CABG

(documented in-stent restenosis)ASA, TP

35 months sudden out-of-hospital death ASA, TP

Causes of Death

Conclusions• The use of BMS was associated with lower long-term mortality than the use of SES for SVG disease.

• Also the 6-month reduction in repeated revascularization procedures shown with the use of SES was lost at longer-term follow-up.

• However:• this is secondary post-hoc analysis,• the play of chance should be strongly considered,• “hidden” factors unrelated to stent type could have influenced the final results.

• Further studies are required before conclusions can be made about the safety or harm of using SES for SVG lesions.

DELAYED-RRISC Investigators

Steering Committee: Pierfrancesco Agostoni, MD Paul Vermeersch, MD

Other Investigators: Stefan Verheye, MD, PhDGlenn Van Langenhove, MD, PhDFrank Van den Branden, MD

Paul Van den Heuvel, MDCarl Convens, MD

Data Monitoring: Christine Jacobs, RNNancy Aerts, RNAnne-Rose Gustin (Incubate, Cardiac Solutions)

CEC Committee: Giuseppe M. Sangiorgi, MDGiuseppe G.L. Biondi-Zoccai, MD

Statistical Analysis: Pierfrancesco Agostoni, MD